Abstract
The present investigation was designed to test whether four cardiac hormones - long
acting natriuretic hormone, vessel dilator, kaliuretic hormone and atrial natriuretic
hormone decrease the circulating concentration of prolactin in humans (n = 30). Vessel
dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic
hormone decreased the circulating concentration of prolactin to 3 %, 31 %, 27 %, and
23 % of control values, respectively, at the end of their infusions when infused at
concentrations of 100 ng/kg body weight per minute for 60 minutes (p < 0.001 for each).
Vessel dilator, kaliuretic hormone, long acting natriuretic hormone and atrial natriuretic
hormone had sustained effects on modulating prolactin’s concentrations, with circulating
concentrations of 1 %, 64 %, 28 %, and 2 % of control values (p < 0.001) 3 hours after
stopping their respective infusions. These results suggest that there are four circulating
prolactin-inhibitory hormones in addition to the hypothalamic mediators, dopamine
and corticotropin-releasing hormone, which modulate prolactin release. These peptide
hormones’ ability to decrease circulating prolactin concentrations may be mediated
in part by dopamine and in part by their demonstrated ability to decrease corticotropin-releasing
hormone concentrations, which stimulate prolactin release.
Key words
Prolactin-Inhibitory Hormones - Corticotropin-Releasing Hormone - Hypothalamus - Natriuretic
Hormones
References
- 1
Ohashi M, Fujio N, Nawata H, Kato K, Matsuo H, Ibayashi H.
Effect of α-human atrial natriuretic polypeptide on anterior pituitary function in
men.
Endocr J.
1987;
34
659-663
- 2
Foresta C, Caretto A, Mioni R, Betterle C, Scandellari C.
Evidence of immunoreactive human atrial peptides in human anterior pituitary cells.
Horm Metab Res.
1988;
20
376-377
- 3
Foresta C, DeCarlo E, Mioni R, Zorzi M, Scandellari C.
Evidence for a dopaminergic involvement in the inhibitory effect of alpha human natriuretic
peptide on prolactin in man.
Horm Metab Res.
1989;
21
630-634
- 4
Wiedemann K, Herzog L, Kellner M.
Atrial natriuretic hormone inhibits corticotropin-releasing hormone-induced prolactin
release in man.
J Psychr Res.
1995;
29
51-58
- 5
Vesely D L.
Atrial Natriuretic Hormones. Englewood Cliffs Prentice Hall.
1992;
1-256
- 6
Standaert D G, Needleman P, Day M L, Weigand R, Krause J E.
Expression of the gene for preproatriopeptin in the central nervous system of the
rat.
Mol Brain Res.
1988;
4
7-13
- 7
Martin D R, Pevahouse J B, Trigg D J, Vesely D L, Buerkert J E.
Three peptides from the ANF prohormone NH2-terminuteus are natriuretic and/or kaliuretic.
Am J Physiol.
1990;
258
F1401-F1408
- 8
Vesely D L, Norris J S, Walters J M, Jespersen R R, Baeyens D A.
Atrial natriuretic prohormone peptides 1 - 30, 31 - 67 and 79 - 98 vasodilate the
aorta.
Biochem Biophys Res Commun.
1987;
148
1540-1548
- 9
Vesely D L, Douglass M A, Dietz J R, Giordano A T, McCormick M T, Rodriguez-Paz G,
Schocken D D.
Negative feedback of atrial natriuretic peptides.
J Clin Endocrinol Metab.
1994;
78
1128-1134
- 10
Vesely D L, Douglass M A, Dietz J R, Gower W R , McCormick M T, Rodriguez-Paz G, Schocken D D.
Three peptides from the atrial natriuretic factor prohormone amino terminus lower
blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans.
Circulation.
1994;
90
1129-1140
- 11
Vesely D L, Dietz J R, Parks J R, Baig M, McCormick M T, Cintron G, Schocken D D.
Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic
effects in persons with congestive heart failure.
Circulation.
1998;
98
323-329
- 12
Vesely D L, Norsk P, Winters C J, Rico D M, Sallman A L, Epstein M.
Increased release of the N-terminal and C -terminal portions of the prohormone of
atrial natriuretic factor during immersion-induced central hypervolemia in normal
humans.
Proc Soc Exp Biol Med.
1989;
192
230-235
- 13
Winters C J, Sallman A L, Baker B J, Meadows J, Rico D M, Vesely D L.
The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus
of the atrial natriuretic factor prohormone each circulate in humans and increase
in congestive heart failure.
Circulation.
1989;
80
438-449
- 14
Hunter E FM, Kelly P A, Prowse C, Woods R J, Lowry P J.
Analysis of peptides derived from pro atrial natriuretic peptide that circulate in
man and increase in heart disease.
Scan J Clin Lab Invest.
1998;
58
205-216
- 15
Ackerman B H, Wyeth R P, Vesely D L, Ngo L, Bissett J K, Winters C H, Sallman A L.
Pharmacokinetic characterization of the post-distribution phase of prohormone atrial
natriuretic peptides amino acids 1 - 98, 31 - 67, and atrial natriuretic factor during
and following rapid right ventricular pacing in dogs.
J Clin Pharmacol.
1992;
32
415-421
- 16
Poulos J E, Gower W R, Sullebarger J T, Fontanet H L, Vesely D L.
Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide
gene expression.
Cardiovasc Res.
1996;
32
909-919
- 17
Dietz J R, Nazian S J, Vesely D L.
Release of ANF, proANF 1 - 98, and proANF 31 - 67 from isolated rat atria by atrial
distention.
Am J Physiol.
1991;
260
H1774-H1778
- 18
Ackerman B H, Overton R M, McCormick M T, Schocken D D, Vesely D L.
Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans
following a one-hour infusion.
J Pharmacol Exp Therap.
1997;
282
603-608
- 19
Schulte H M, Chrousos G P, Gold P W, Oldfield E H, Hoban M C, Cutler G B, Loriaux D L.
Corticotropin-releasing factor (CRF): A common link between anterior pituitary and
sympathetic responses to stress.
Acta Endocrinol.
1983;
102 (Suppl 253)
32-33
- 20
Vesely D L, San Miguel G I, Hassan I, Schocken D D.
Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic
hormone decrease the circulating concentrations of corticotropin-releasing hormone,
corticotropin and cortisol.
J Clin Endocrinol Metab.
2001;
86
4244-4249
- 21
Flores C M, Hulihan-Giblin G A, Homby P J, Lumpkin M D, Kellar K J.
Partial characterization of the neurotransmitter pathway regulating the in vitro release of prolactin.
Neuroendocrinology.
1992;
55
519-528
- 22
Sampson W K, Bianchi R.
Further evidence for a hypothalamic site of action of atrial natriuretic factor: inhibition
of prolactin secretion in the conscious rat.
Can J Physiol Pharmacol.
1988;
66
301-305
- 23
Sampson W K, Bianchi R, Mogg R.
Evidence for a dopaminergic mechanism for the prolactin inhibitory effect of atrial
natriuretic factor.
Neuroendocrinology.
1988;
47
268-271
- 24
Kadowaki K, Hirota K, Koike K, Ohmichi M, Miyake A, Tanizawa O.
Atrial and brain natriuretic peptides enhance dopamine accumulation in cultured hypothalamic
cells including dopaminergic neurons.
Neuroendocrinology.
1992;
56
11-17
- 25
Nakao K, Katsura G, Mori N, Itoh H, Shiono S, Yamada T, Sugawara A, Sakamoto M, Saito Y,
Eigyo M, Matsushita A, Imura H.
Inhibitory effect of centrally administered atrial natriuretic polypeptide on brain
dopaminergic system in rats.
Eur J Pharmacol.
1986;
131
171-177
- 26
Kawata M, Nakao K, Morii N, Kiso Y, Yamashita H, Imura H, Sano Y.
Atrial natriuretic polypeptide: Topographical distribution in the rat brain by radioimmunoassay
and immunochemistry.
Neuroscience.
1985;
16
521-546
- 27
Kurihara M, Saavedra J M, Shigematsu K.
Localization and characterization of atrial natriuretic peptide binding sites in discrete
areas of rat brain and pituitary gland by quantitative autoradiography.
Brain Res.
1987;
408
31-39
- 28
Koch B, Boudjada T, Lutz-Bucher B.
Characterization of high affinity receptor sites for atrial natriuretic factor in
anterior pituitary gland: evidence for the existence of two receptor forms.
Biochem Biophys Res Commun.
1988;
152
904-909
- 29
Wilcox J N, Augustine A, Goeddel D V, Lowe D G.
Differential regional expression of three natriuretic peptide receptor genes within
primate tissues.
Mol Cell Biol.
1991;
11
3454-3462
- 30
Grandclement B, Brisson C, Bayard G, Tremblay J, Gossard F, Morel G.
Localization of mRNA coding for three subtypes of atrial natriuretic factor (ANF)
receptors in rat anterior pituitary gland cells.
J Neuroendocrinol.
1995;
7
939-948
- 31
Gutkowska J, Antunes-Rodrigues J, McCann S M.
Atrial natriuretic peptide in brain and pituitary gland.
Physiological Rev.
1997;
77
465-515
- 32
Edwards A V, Ghatei M A, Bloom S R.
The effect of splanchnic nerve stimulation on the uptake of atrial natriuretic peptide
by the adrenal gland of conscious calves.
J Endocrinol Invest.
1990;
13
887-892
- 33
Duntas L, Bornstein S R, Scherbaum W A, Holst J J.
Atrial natriuretic peptide-like immunoreactive material (ANP-LI) is released from
the adrenal gland by splanchnic stimulation. Exp & Clin.
Endocrinol.
1993;
101
371-373
- 34 Katznelson L, Klibanski A.
Prolactin and its disorders. In: Principles and Practice of Endocrinology and Metabolism. Becker KL (ed) .Philadelphia;
J B Lippincott Co. 1995: 140-147
- 35
Vesely D L, Winters C J, Sallman A L.
Prohormone atrial natriuretic peptides 1 - 30 and 31 - 67 increase in hyperthyroidism
and decrease in hypothyroidism.
Am J Med Sci.
1989;
297
209-215
- 36
Honbo K S, Herle A JV, Kellett K A.
Serum prolactin levels in untreated primary hypothyroidism.
Am J Med.
1978;
64
782-787
D. L. Vesely, M.D., Ph.D.
Chief, Endocrinology, Diabetes & Metabolism · James A. Haley Veterans Hospital-151
13000 Bruce B. Downs Blvd. · Tampa, Florida 33612 · USA ·
Telefon: + 1 (813) 972-7624
Fax: + 1 (813) 972-7623
eMail: vesely.david_l@tampa.va.gov
